-
公开(公告)号：US11969444B2
公开(公告)日：2024-04-30
申请号：US17819214
申请日：2022-08-11
发明人： Ian Frank , Michael T. Lotze
IPC分类号： A61K35/17 , A01N1/02 , A61P35/00 , C07K14/725 , C07K16/00 , C12N5/0783 , C12N15/85 , G01N33/50
CPC分类号： A61K35/17 , A01N1/0284 , A61P35/00 , C07K14/7051 , C07K16/00 , C12N5/0636 , C12N15/85 , G01N33/5005 , C07K2317/24 , C07K2319/03 , C07K2319/33 , C12N2501/04 , C12N2501/2302 , C12N2502/11 , C12N2502/1121 , C12N2502/99
摘要： The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
-
公开(公告)号：US20240076616A1
公开(公告)日：2024-03-07
申请号：US18262268
申请日：2022-01-21
申请人： Cytovac A/S
发明人： Alexei Kirkin
IPC分类号： C12N5/0783 , A61K35/17 , C12N5/00
CPC分类号： C12N5/0636 , A61K35/17 , C12N5/0018 , C12N2501/02 , C12N2501/22 , C12N2501/2301 , C12N2501/2302 , C12N2501/2304 , C12N2501/2306 , C12N2501/2312 , C12N2501/25 , C12N2502/1121
摘要： Provided is a method for preparation of a composition comprising activated human CD4+ and CD8+ lymphocytes. The method entails use of allogeneic mature dendritic cells as feeder cells added at an early stage in the induction of proliferation and activation of CD4+ and CD8+ T cells. Further provided is a method for treatment of lymphopenia related diseases by infusion of the cells obtained from the present process.
-
公开(公告)号：US11873510B2
公开(公告)日：2024-01-16
申请号：US16879923
申请日：2020-05-21
发明人： Bellur Prabhakar
IPC分类号： C12N5/0783 , A61P37/02 , A61K35/17 , A61K35/28
CPC分类号： C12N5/0637 , A61K35/17 , A61K35/28 , A61P37/02 , C12N2501/22 , C12N2501/415 , C12N2501/998 , C12N2501/999 , C12N2502/08 , C12N2502/1121 , A61K35/17 , A61K2300/00 , A61K35/28 , A61K2300/00
摘要： This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases.
-
公开(公告)号：US20240000936A1
公开(公告)日：2024-01-04
申请号：US18310649
申请日：2023-05-02
IPC分类号： A61K39/00 , C12N5/0783 , A61P31/22 , A61P35/00
CPC分类号： A61K39/4611 , C12N5/0636 , A61K39/464838 , A61P31/22 , A61P35/00 , A61K39/464449 , A61K39/46444 , A61K39/464402 , A61K39/464452 , C12N2502/1121 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/2321 , A61K2239/57 , A61K2239/26
摘要： The invention described herein provide Kaposi Sarcoma-Associated Herpesvirus (KSHV) oncoprotein antigens and epitopes for expanding antigen-specific T cells. Such expanded T cells are useful for, e.g., in allogeneic or “off-the-shelf” adoptive T cell therapy.
-
公开(公告)号：US11773372B2
公开(公告)日：2023-10-03
申请号：US17211863
申请日：2021-03-25
发明人： Yair Reisner , Noga Or-Geva , Rotem Gidron Budovsky , Esther Bachar-Lustig , Assaf Lask , Sivan Kagan
IPC分类号： C12N5/0783 , A61K35/17 , A61K39/00 , C12N5/00 , A61K35/12
CPC分类号： C12N5/0637 , A61K35/17 , A61K39/001 , C12N5/0087 , A61K2035/122 , A61K2039/5158 , C12N2501/2307 , C12N2501/2315 , C12N2501/2321 , C12N2502/1121
摘要： A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
-
公开(公告)号：US20190247430A1
公开(公告)日：2019-08-15
申请号：US16395627
申请日：2019-04-26
IPC分类号： A61K35/15 , A61K49/00 , C12N5/0784
CPC分类号： A61K35/15 , A61K49/0008 , A61K2035/122 , A61K2035/124 , A61K2039/5154 , C12N5/0639 , C12N2501/22 , C12N2501/24 , C12N2502/1121 , C12N2510/00
摘要： The present invention relates to cells engineered to express at least one cytokine and at least one antigen which induces the self differentiation of dendritic cell (DC) progenitor cells into functional antigen-presenting induced DC (iDC). Moreover, therapeutic uses of said iDC for regenerating the immune system after transplantation of hematopoietic stem cells are disclosed. Said iDC are also useful for generating mice with a functional endogenously regenerated humanized immune system producing antigen-specific T and B cell responses which can be used as animal models for the study of the human adaptive immune responses.
-
7.发明申请公开(公告)号：US20180193384A1
公开(公告)日：2018-07-12
申请号：US15825275
申请日：2017-11-29
发明人： Yair REISNER , Yaki EIDELSTEIN , Eran OPHIR , Assaf LASK , Ran AFIK , Noga OR-GEVA , Esther BACHAR-LUSTIG
IPC分类号： A61K35/17 , A61K39/00 , A61K35/26 , A61K35/28 , A61K35/34 , A61K35/36 , A61K35/38 , A61K35/39 , C12N5/0783 , A61K35/22 , A61K35/42 , A61K35/407 , A61K35/12
CPC分类号： A61K35/17 , A61K35/22 , A61K35/26 , A61K35/28 , A61K35/34 , A61K35/36 , A61K35/38 , A61K35/39 , A61K35/407 , A61K35/42 , A61K39/001 , A61K2035/122 , A61K2035/124 , A61K2039/5158 , C12N5/0636 , C12N5/0637 , C12N2501/2307 , C12N2501/2315 , C12N2501/2321 , C12N2502/1121
摘要： A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
-
公开(公告)号：US20180135011A1
公开(公告)日：2018-05-17
申请号：US15802100
申请日：2017-11-02
发明人： Yelena Bronevetsky , Xiaohua Wang , Peter J. Beemiller , Kristin G. Beaumont , Randall D. Lowe, JR. , Alexander J. Mastroianni , Kevin T. Chapman
IPC分类号： C12N5/0783 , A61P35/00 , C12M3/06 , A61K39/00 , C12M1/00
CPC分类号： C12N5/0636 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5158 , A61P35/00 , C12M23/16 , C12M29/10 , C12N2501/2302 , C12N2501/51 , C12N2501/515 , C12N2502/1121 , C12N2533/50
摘要： Methods of expanding T lymphocytes in a microfluidic device are provided. The methods can include introducing one or more T lymphocytes into a microfluidic device; contacting the one or more T lymphocytes with an activating agent; and perfusing culture medium through the microfluidic device for a period of time sufficient to allow the one or more T lymphocytes to undergo at least one round of mitotic cell division. The expansion can be non-specific or antigen-specific. T lymphocytes produced according to the disclosed methods are also provided, along with methods of treating cancer in a subject. The methods of treating cancer can include isolating T lymphocytes from a tissue sample obtained from the subject; expanding the isolated T lymphocytes in a microfluidic device; exporting the expanded T lymphocytes from the microfluidic device; and reintroducing the expanded T lymphocytes into the subject.
-
9.发明申请公开(公告)号：US20170267972A1
公开(公告)日：2017-09-21
申请号：US15326968
申请日：2015-07-17
申请人： Hiroshi Kawamoto
发明人： Hiroshi Kawamoto , Shin Kaneko , Kyoko Masuda , Takuya Maeda , Seiji Nagano , Yoshimoto Katsura
IPC分类号： C12N5/0783 , A61K39/00
CPC分类号： C12N5/0638 , A61K35/17 , A61K39/0011 , A61K2039/5158 , A61K2039/585 , A61P31/12 , A61P35/00 , A61P37/08 , C12N15/09 , C12N2502/1121 , C12N2506/45
摘要： Provided is a method for inducing T cells for use in a cell-based immunotherapy, comprising the steps of:(1) providing human pluripotent stem cells bearing a T cell receptor specific for a WT1 antigen or an Epstein-Barr virus associated antigen, and (2) inducing T cell progenitors or mature T cells from the pluripotent stem cells provided in step (1). Pluripotent stem cells may preferably be iPS cells. The human pluripotent stem cells bearing a T cell receptor specific for an antigen may be prepared by inducing iPS cells from a T cell having the desired antigen specificity or by introducing genes encoding the T cell receptor specific for the desired antigen into iPS cells. The T cells obtained by this method can be used for the treatment of various immune-related diseases such as cancers and infectious diseases.
-
公开(公告)号：US09625444B2
公开(公告)日：2017-04-18
申请号：US14221018
申请日：2014-03-20
发明人： William L Warren , Heather Fahlenkamp , Russell Higbee , Anatoly Kachurin , Conan Li , Mike Nguyen , Robert Parkhill , Guzman Sanchez-Schmitz , Darrell J. Irvine , Gwendalyn J. Randolph , Nir Hacohen , Bruce Torbett
CPC分类号： G01N33/5008 , C12N5/0697 , C12N5/0698 , C12N2501/21 , C12N2502/094 , C12N2502/11 , C12N2502/1107 , C12N2502/1114 , C12N2502/1121 , C12N2502/1157 , C12N2502/1192 , C12N2502/1323 , C12N2502/28 , C12N2503/04 , C12N2513/00 , C12N2531/00 , C12N2533/50 , C12N2533/54 , C12N2535/10 , G01N33/5088 , G01N2500/10
摘要： The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.
-
-
-
-
-
-
-
-
-
搜索结果
151 条记录 (耗时 0.034 秒)
